Business Wire

SINGAPORE--(BUSINESS WIRE)-- Charles River Development (CRD), a State Street Company, has appointed Vinayak Bhat (Vin) as senior vice president (SVP), head of Asia Pacific (APAC), where he will be responsible for all business oversight within the region and collaboration with State Street Alpha®, the first front-to-back asset servicing platform from a single provider for institutional investors. Charles River, provider of the Charles River Investment Management... (continue reading...)

Company enters into definitive agreement to be acquired by EQT for approximately $3 Billion

ST. LOUIS--(BUSINESS WIRE)-- Perficient, Inc. (Nasdaq: PRFT) (“Perficient”), the leading global digital consultancy transforming the world’s largest enterprises and biggest brands, today reported its financial results for the quarter ended March 31, 2024.

Financial Highlights

For the quarter ended March 31, 2024:

• Revenues decreased 7% to $215.3 million from... (continue reading...)

Reports First Quarter Fiscal Year 2024 Financial Results

ST. LOUIS--(BUSINESS WIRE)-- Perficient, Inc. (Nasdaq: PRFT) (“Perficient” or “the Company”), a leading global digital consultancy transforming the world’s largest enterprises and biggest brands, today announced that it has entered into a definitive agreement to be acquired by an affiliate of BPEA Private Equity Fund VIII (“EQT Asia”), part of EQT AB, a purpose-driven global investment... (continue reading...)

– Smith to join influential thought leaders and innovators in addressing critical global issues –

NEW YORK & LOS ANGELES--(BUSINESS WIRE)-- Garrett Smith, Founder and CEO of Community Capital Technology Inc. (“Community Capital”), will be attending the Milken Institute Global Conference (“MI Global”) May 5-8, 2024 in Los Angeles. The event brings together global executives and visionaries to discuss developing a shared future and using disruptions to... (continue reading...)

• There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location
• RFS Was 100% in Patients who Received Maintenance therapy vs 61% for Patients Who Did Not Receive Maintenance Therapy

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today... (continue reading...)